Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TCX-101
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Thuja Capital
Deal Size : $15.0 million
Deal Type : Financing
Tacalyx extends seed funding round to raise over €14m
Details : Tacalyx will use the funding to develop pipeline candidates including, TCX-101, a novel antibody-drug conjugate targeting a tumor- associated carbohydrate antigen for the treatment of solid tumors.
Product Name : TCX-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 06, 2024
Lead Product(s) : TCX-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Thuja Capital
Deal Size : $15.0 million
Deal Type : Financing
Reset All
